Search PubMed⌕ Search

Biomedical subjects

H Pakkenberg

Publications and source records attributed to H Pakkenberg.

At least 55 records · Page 3Linked to original sources
PubMed1980

Theoretical and clinical aspects of the Tourette syndrome (chronic multiple tic).

In three schizophrenic patients long-term neuroleptic treatment induced Tourette-like symptoms. There seems to be a partial overlap in the pathogenesis of Tourette syndrome and tardive dyskinesia. In five Tourette patients treatment with pimozide was very effective inducing only few side-effects. Long-term neuroleptic treatment may, however, aggravate the symptoms in the long run. A combination treatment with tetrabenazine and pimozide is suggested.

Adolescent↗
PubMed1980

Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease.

Salivary and plasma concentrations of bromocriptine (BCT), a dopamine agonist, were measured by gas chromatography in four patients with Parkinson's disease. All the patients had been on mono-therapy with BCT for years, and during the 3 weeks prior to the investigation they received constant but individually different dosage regimens. Paired samples of pure, parotid, serous saliva and of blood were collected hourly during one eight hour dose interval. The concentrations of BCT in saliva were very low and there was a ten-fold range in the areas under the salivary and plasma concentration/time curves. It is concluded that in clinical practice measurement of BCT in saliva is not suitable for exact estimation of the plasma concentration of BCT. Using the measured salivary pH and the plasma BCT concentration, calculations based on the Henderson-Hasselbalch equation showed that the assumption of about 99% plasma protein binding of BCT best fited the observed concentrations of BCT in saliva.

Aged↗
PubMed1980

Bromocriptine and Parkinson's disease: a 16-hour clinical evaluation.

The disability score (Webster rating scale) in 12 parkinsonian patients on bromocriptine treatment was evaluated hourly from 06-22 h. Bromocriptine was taken at fixed hours (06, 14, and 22 h) in equal doses. No systematic changes during the day related to bromocriptine ingestion were observed. Only one patient experienced pronounced hyperkinesia, "On-off" phenomenas were not observed during the treatment with bromocriptine.

Aged↗
PubMed1979

Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.

The plasma kinetics of bromocriptine (BCT), a long-acting dopamine agonist, was studied in twelve patients with Parkinson's disease, using a newly developed gas chromatographic method of analysis. Each patient received BCT for at least three weeks in a constant but different dose regimen. Concomitant treatment with 1-DOPA was not allowed. During a 6-day hospitalization period, a blood sample was taken immediately before the afternoon dose at 14.00 h (Cmin) to determine the steady-state level. On the 6th day blood samples were collected every hour during two 8 h dose intervals. The results showed a significant correlation between the mean values of the AUC and the Cmin. First order elimination kinetics appeared to be followed by BCT, at least for the plasma concentrations commonly found. Considerable inter-individual variation was demonstrated both for the dose/plasma concentration ratio and for calculated plasma clearances. No serious side-effects were observed during the investigation.

Aged↗
PubMed1979

Topographical distribution of arsenic, manganese, and selenium in the normal human brain.

The concentrations of arsenic, manganese and selenium per gram wet tissue weight were determined in samples from 24 areas of normal human brain from 5 persons with ages ranging from 15 to 81 years of age. The concentrations of the 3 elements were determined for each sample by means of neutron activation analysis with radiochemical separation. Distinct patterns of distribution were shown for each of the 3 elements. Variations between individuals were found for some but not all brain areas, resulting in coefficients of variation between individuals of about 30% for arsenic, 10% for manganese and 20% for selenium. The results seem to indicate that arsenic is associated with the lipid phase, manganese with the dry matter and selenium with the aqueous phase of brain tissue.

Adolescent↗
PubMed1976

High-dose treatment of rats with perphenazine enanthate.

Previously we demonstrated an approximately 20% loss of nerve cells in the basal ganglia of rats following treatment with perphenazine enanthate 3.4 mg/kg s.c. every 2nd week during 12 months. If the treatment period was only 2 or 3 months no significant differences were found.

Animals↗
PubMed1976

Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.

92 patients with Parkinson's disease not previously treated with levodopa were considered as eligible for this triple-blind trial. Patients were allocated at random to treatment with either levodopa + benserazide ratio 4:1 (Madopar) or levodopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules recommended by the manufacturers which they had to adhere to for 6 months. Unless prohibitive side-effects occurred daily maximum dosage of 800 mg levodopa + 200 mg benserazide respectively 1,500 mg levodopa + 150 mg carbidopa were obtained after 6 weeks and 3 weeks, respectively. The effect of the two schedules on the Parkinsonian symptoms were equal and appeared equally fast. The frequency of gastrointestinal side-effects and involuntary movements were significantly higher and more severe for Sinemet than for Madopar. These side effects are usually symptoms of levodopa overdosing, but whether or not a different dosage schedule with Sinemet would have given fewer side-effects without concurrent lower efficacy remains open to speculation. The treatment schedules did not differ with regard to other side-effects and influence on blood pressure. Neither treatment seemed to influence liver function, renal function and hematological parameters in a statistically way.

Aged↗
PubMed1975

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide proved superior to levodopa on several accounts. Nausea and vomiting occurred with statistically significant less severity and frequency. Clinical improvement expressed through improvement in Webster rating occurred sooner and was all together greater. The treatment schedules did not differ with regard to other side effects, in particular involuntary movements and reduction in supine blood pressure. Neither treatment seemed to influence liver function, renal function and hematological parameters.

Adult↗